Heparin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Heparin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Overview:

The global heparin market size reached US$ 7.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.3 Billion by 2028, exhibiting a growth rate (CAGR) of 2.4% during 2023-2028.

Heparin, denoted by the chemical formula C12H19NO20S3, is a sulfur-containing polysaccharide that acts as an anticoagulant or a blood thinner. It prevents the formation of blood clots inside blood vessels and is used for the treatment of heart conditions and unstable angina. It is also used in post-surgeries as well as during dialysis and blood transfusion. Heparin is usually injected directly into the muscle or the veins to break up clots and maintain smooth fluidity of the blood. Some common side-effects of using heparin include easy bruising and itchy skin with redness.

The rising prevalence of various medical ailments such as deep vein thrombosis (DVT) and pulmonary embolism (PE) is one of the key factors driving the global market. Also, heparin has been proven to be an extremely effective drug for venous thromboembolism and cardiovascular disorders (CVDs), which is contributing significantly to its market growth. Furthermore, biopharmaceutical companies are developing innovative medicines to enhance the therapeutic potential of heparin and reduce its side-effects. Availability of synthetic and semi-synthetic heparin mimetics that assist in treating various cancers, coagulation and inflammatory diseases is significantly increasing the adoption of the product. The market is further driven by the various advancements in the field of carbohydrate synthesis, which include building block preparation, coupling reactions and the development of convergent strategies. Moreover, increasing government funding toward improving healthcare facilities and extensive research and development (R&D) activities to develop heparin with ultra-low molecular weight for utilization in chemotherapy are also creating a positive outlook for the market. 

IMARC Group’s latest report provides a deep insight into the global heparin market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the heparin market in any manner. 

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global heparin market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on product, source, mode of administration, application, end-user and distribution channel.

Breakup by Product:

Unfractionated Heparin 
Low Molecular Weight Heparin (LMWH)
Ultra-Low Molecular Weight Heparin (ULMWH)

Breakup by Source:

Bovine
Porcine

Breakup by Mode of Administration:

Oral
Parenteral

Breakup by Application:

Atrial Fibrillation & Heart Attack
Stroke
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Others

Breakup by End-User:

Hospitals
Clinics
Homecare Settings
Ambulatory Surgical Centers
Others

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Stores
Others

Breakup by Region:

Europe
North America
Asia Pacific
Middle East and Africa
Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being GlaxoSmithKline Plc, Shenzhen Hepalink Pharmaceutical Co., Ltd, Pfizer Inc., LEO Pharma A/S, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Baxter International Inc., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Sandoz International GmbH, Opocrin S.p.A., Sichuan Deebio Pharmaceutical Co., Ltd. and Dongying Tiandong Pharmaceutical Co., Ltd.

Key Questions Answered in This Report:

How has the global heparin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global heparin industry?
What are the key regional markets in the global heparin industry?
What is the breakup of the market based on the product?
What is the breakup of the market based on the source?
What is the breakup of the market based on the mode of administration?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end-user?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the global heparin industry?
What are the key driving factors and challenges in the global heparin industry?
What is the structure of the global heparin industry and who are the key players?
What is the degree of competition in the global heparin industry?